These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30461207)

  • 81. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
    Planting AS; Catimel G; de Mulder PH; de Graeff A; Höppener F; Verweij J; Oster W; Vermorken JB
    Ann Oncol; 1999 Jun; 10(6):693-700. PubMed ID: 10442192
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Amifostine: the first selective-target and broad-spectrum radioprotector.
    Kouvaris JR; Kouloulias VE; Vlahos LJ
    Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
    Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
    Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
    Noël G; Mazeron JJ
    Cancer Radiother; 2001 Apr; 5(2):202-4. PubMed ID: 11355589
    [No Abstract]   [Full Text] [Related]  

  • 85. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
    Rodrigues NA; Killion L; Hickey G; Silver B; Martin C; Stevenson MA; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1079-83. PubMed ID: 19327910
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study.
    Grötz KA; Wüstenberg P; Kohnen R; Al-Nawas B; Henneicke-von Zepelin HH; Bockisch A; Kutzner J; Naser-Hijazi B; Belz GG; Wagner W
    Br J Oral Maxillofac Surg; 2001 Feb; 39(1):34-9. PubMed ID: 11178853
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
    Samuels MA
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):318; author reply 318-9. PubMed ID: 17707287
    [No Abstract]   [Full Text] [Related]  

  • 90. Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
    J Support Oncol; 2006 Feb; 4(2):88. PubMed ID: 16499131
    [No Abstract]   [Full Text] [Related]  

  • 91. Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial.
    Garcia MK; Meng Z; Rosenthal DI; Shen Y; Chambers M; Yang P; Wei Q; Hu C; Wu C; Bei W; Prinsloo S; Chiang J; Lopez G; Cohen L
    JAMA Netw Open; 2019 Dec; 2(12):e1916910. PubMed ID: 31808921
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pathophysiology and management of radiation-induced xerostomia.
    Berk LB; Shivnani AT; Small W
    J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.
    Katsanos KH; Briasoulis E; Tsekeris P; Batistatou A; Bai M; Tolis C; Capizzello A; Panelos I; Karavasilis V; Christodoulou D; Tsianos EV
    J Exp Clin Cancer Res; 2010 Jun; 29(1):68. PubMed ID: 20537164
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
    Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
    Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
    Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
    Ma C; Xie J; Chen Q; Wang G; Zuo S
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007956. PubMed ID: 19821441
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study.
    Poulsen M; Denham J; Spry N; Lamb D; Peters L; Krawitz H; Penniment M; Williamson S; Tripcony L
    Australas Radiol; 1999 Nov; 43(4):487-94. PubMed ID: 10901965
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Intensity-Modulated Radiation Therapy Alone Versus Intensity-Modulated Radiation Therapy and Brachytherapy for Early-Stage Oropharyngeal Cancers: Results From a Randomized Controlled Trial.
    Budrukkar A; Murthy V; Kashid S; Swain M; Rangarajan V; Laskar SG; Kannan S; Kale S; Upreti R; Pai P; Pantvaidya G; Gupta T; Agarwal JP
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1541-1551. PubMed ID: 37660737
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Two-Year Tumor Outcomes of a Phase 2B, Randomized, Double-Blind Trial of Avasopasem Manganese (GC4419) Versus Placebo to Reduce Severe Oral Mucositis Owing to Concurrent Radiation Therapy and Cisplatin for Head and Neck Cancer.
    Anderson CM; Lee CM; Saunders D; Curtis AE; Dunlap NE; Nangia C; Lee AS; Kovoor P; Bar-Ad V; Pedadda AV; Holmlund J; Downs M; Sonis ST
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):416-421. PubMed ID: 35724774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.